DVAのニュース
Medtronic, DaVita jointly launch kidney-care company Mozarc Medical 2023/04/03 19:04:35 Business Journals
Med-tech manufacturer Medtronic and DaVita Inc. have announced the launch of their new medical technology company focused on kidney health.
DaVita Inc. (NYSE:DVA) Shares Sold by Hartford Investment Management Co. 2023/04/03 09:00:41 The AM Reporter
Hartford Investment Management Co. trimmed its position in DaVita Inc. (NYSE:DVA – Get Rating) by 65.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,484 shares of the company’s stock after selling 8,396 shares during the period. Hartford Investment Management Co.’s holdings in […]
Medtronic, DaVita launch Mozarc Medical, aimed at introducing new solutions for patients with kidney failure 2023/04/01 16:00:00 PR Newswire
New, independent kidney health technology company will combine expertise from two industry leaders to drive care transformation DUBLIN and DENVER, April 1, 2023 /PRNewswire/ -- Medtronic plc (NYSE: MDT) and DaVita Inc. (NYSE: DVA) today announced the launch of Mozarc Medicalan…
Medtronic, DaVita launch Mozarc Medical, aimed at introducing new solutions for patients with kidney failure 2023/04/01 16:00:00 Kwhen Finance
Warner Bros. Discovery and GroupM Partner to Amplify Diverse Voices 2023/03/06 20:30:00 Adweek
Warner Bros. Discovery and GroupM are looking to invest in more diverse voices. Top line Today, GroupM announced that GroupM Motion Entertainment is partnering with Warner Bros. Discovery to support the WPP media investment group''s Diverse Voices Accelerator (DVA), an initiative that supports creators, writers, producers, directors and studios from traditionally underrepresented groups. Between the…
DaVita Inc. Schedules 4th Quarter 2022 Investor Conference Call 2023/02/01 10:00:00 PR Newswire
DENVER, Feb. 1, 2023 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss fourth quarter and full year results on Wednesday, February 22, 2023, at 5:00 p.m. Eastern Time. The company plans to release its results after the…
Pathalys Pharma Raises $150M in Secured Product Financing and Equity 2023/01/20 11:41:55 FinSMEs
Pathalys Pharma, a Raleigh, NC-based private, late-stage biopharma company, raised $150M in Secured Product financing and equity funding. Abingworth led both financings and was joined by Carlyle and OrbiMed, along with Pathalys’ founding investors Catalys Pacific and DaVita Venture Group. The company intends to use the funds to support the two phase 3 clinical trials, […] The post Pathalys Pharma Raises $150M in Secured Product Financing and Equity appeared first on FinSMEs .
What Makes DaVita (DVA) a Good Investment Choice? 2023/01/17 12:15:49 Insider Monkey
Moon Capital Management, an investment management company, released its fourth-quarter 2022 investor letter. A copy of the same can be downloaded here. For the year 2022, the S&P 500 declined almost 20%, which was the largest annual decline since the 2008 Great Recession. The fund declined by approximately 7% for the same period. In addition, you […]
Here''s How Much You Would Have Made Owning DaVita Stock In The Last 20 Years 2023/01/11 15:03:59 Benzinga
DaVita (NYSE: DVA ) has outperformed the market over the past 20 years by 4.26% on an annualized basis producing an average annual return of 11.95%. Currently, DaVita has a market capitalization of $7.17 billion. Buying $100 In DVA: If an … Full story available on Benzinga.com
DaVita (DVA): A Favorite Of Berkshire Investment Manager Is Undervalued 2022/12/15 06:32:18 Seeking Alpha
Berkshire has held shares in DaVita since 2011, presumably picked by Ted Weschler. See why right now is a good opportunity to buy DVA shares on an intrinsic basis.
DaVita (DVA): A Favorite Of Berkshire Investment Manager Is Undervalued 2022/12/15 06:32:18 Seeking Alpha
Berkshire has held shares in DaVita since 2011, presumably picked by Ted Weschler. See why right now is a good opportunity to buy DVA shares on an intrinsic basis.
DaVita (DVA): Shares Still Cheap After Outlook Cut, Technicals Suggest Caution 2022/12/12 03:38:34 Seeking Alpha
With impressive free cash flow expected to offer upside potential, risks are seen in DaVita''s chart. See why I am keeping my hold recommendation for DVA stock.
DaVita Inc. – Consensus Indicates Potential 13.0% Upside 2022/12/06 13:50:35 DirectorsTalk
DaVita Inc. with ticker code (DVA) have now 7 analysts in total covering the stock. The consensus rating is ''Hold''. The range between the high target price and low target price is between 109 and 72 calculating the mean target price we have 84. Now with the previous closing price of 74.34 this would imply there is a potential upside of 13.0%. There is a 50 day moving average of 79.67 and the 200 moving average now moves to 93.55. The company has a market capitalisation of $6,618m. You can visit the company''s website by visiting: https://www.davita.com [stock_market_widget type="chart" template="basic" color="green" assets="DVA" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $7,478m based on the market concensus. 0 This article DaVita Inc. – Consensus Indicates Potential 13.0% Upside first appeared on DirectorsTalk Interviews .
Cetera Investment Advisers Cuts Holdings in DaVita Inc 2022/12/03 13:07:10 Business Mag
Cetera Investment Advisers decreased its stake in shares of DaVita Inc. by 7.3% during the 2nd quarter, according to the company in its most recent filing with the Securities…
$1000 Invested In This Stock 20 Years Ago Would Be Worth $8,500 Today 2022/11/21 19:30:55 Benzinga
DaVita (NYSE: DVA ) has outperformed the market over the past 20 years by 3.72% on an annualized basis producing an average annual return of 11.16%. Currently, DaVita has a market capitalization of $6.39 billion. Buying $1000 In DVA: If an … Full story available on Benzinga.com